Upregulation of CRABP1 in Human Neuroblastoma Cells Overproducing the Alzheimer-typical Abeta42 Reduces Their Differentiation Potential

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2008 Dec 18

PMID 19087254

Citations 4

Authors

Markus Uhrig

Peter Brechlin

Olaf Jahn

Yuri Knyazev

Annette Weninger

Laura Busia

Kamran Honarnejad

Markus Otto

Tobias Hartmann

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is characterized by neurodegeneration and changes in cellular processes, including neurogenesis. Proteolytic processing of the amyloid precursor protein (APP) plays a central role in AD. Owing to varying APP processing, several beta-amyloid peptides (Abeta) are generated. In contrast to the form with 40 amino acids (Abeta40), the variant with 42 amino acids (Abeta42) is thought to be the pathogenic form triggering the pathological cascade in AD. While total-Abeta effects have been studied extensively, little is known about specific genome-wide effects triggered by Abeta42 or Abeta40 derived from their direct precursor C99.

Methods: A combined transcriptomics/proteomics analysis was performed to measure the effects of intracellularly generated Abeta peptides in human neuroblastoma cells. Data was validated by real-time polymerase chain reaction (real-time PCR) and a functional validation was carried out using RNA interference.

Results: Here we studied the transcriptomic and proteomic responses to increased or decreased Abeta42 and Abeta40 levels generated in human neuroblastoma cells. Genome-wide expression profiles (Affymetrix) and proteomic approaches were combined to analyze the cellular response to the changed Abeta42- and Abeta40-levels. The cells responded to this challenge with significant changes in their expression pattern. We identified several dysregulated genes and proteins, but only the cellular retinoic acid binding protein 1 (CRABP1) was up-regulated exclusively in cells expressing an increased Abeta42/Abeta40 ratio. This consequently reduced all-trans retinoic acid (RA)-induced differentiation, validated by CRABP1 knock down, which led to recovery of the cellular response to RA treatment and cellular sprouting under physiological RA concentrations. Importantly, this effect was specific to the AD typical increase in the Abeta42/Abeta40 ratio, whereas a decreased ratio did not result in up-regulation of CRABP1.

Conclusion: We conclude that increasing the Abeta42/Abeta40 ratio up-regulates CRABP1, which in turn reduces the differentiation potential of the human neuroblastoma cell line SH-SY5Y, but increases cell proliferation. This work might contribute to the better understanding of AD neurogenesis, currently a controversial topic.

Citing Articles

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

He M, Cao C, Ni Z, Liu Y, Song P, Hao S Signal Transduct Target Ther. 2022; 7(1):181.

PMID: 35680848 PMC: 9178337. DOI: 10.1038/s41392-022-00999-9.

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming.

Tao L, Moreno-Smith M, Ibarra-Garcia-Padilla R, Milazzo G, Drolet N, Hernandez B Adv Sci (Weinh). 2021; 8(19):e2005047.

PMID: 34365742 PMC: 8498874. DOI: 10.1002/advs.202005047.

A mid-life vitamin A supplementation prevents age-related spatial memory deficits and hippocampal neurogenesis alterations through CRABP-I.

Touyarot K, Bonhomme D, Roux P, Alfos S, Lafenetre P, Richard E PLoS One. 2013; 8(8):e72101.

PMID: 23977218 PMC: 3747058. DOI: 10.1371/journal.pone.0072101.

CRABP-II methylation: a critical determinant of retinoic acid resistance of medulloblastoma cells.

Fu Y, Wang Q, Ma J, Yang X, Wu M, Zhang K Mol Oncol. 2011; 6(1):48-61.

PMID: 22153617 PMC: 5528385. DOI: 10.1016/j.molonc.2011.11.004.

References

Grimm H, Beher D, Lichtenthaler S, Shearman M, Beyreuther K, Hartmann T . gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J Biol Chem. 2003; 278(15):13077-85. DOI: 10.1074/jbc.M210380200. View

Gunawardena S, Goldstein L . Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001; 32(3):389-401. DOI: 10.1016/s0896-6273(01)00496-2. View

Kondo M, Shibata T, Kumagai T, Osawa T, Shibata N, Kobayashi M . 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A. 2002; 99(11):7367-72. PMC: 124237. DOI: 10.1073/pnas.112212599. View

Sasaki S, Warita H, Abe K, Iwata M . Slow component of axonal transport is impaired in the proximal axon of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. 2004; 107(5):452-60. DOI: 10.1007/s00401-004-0838-y. View

Dencker L, Annerwall E, Busch C, Eriksson U . Localization of specific retinoid-binding sites and expression of cellular retinoic-acid-binding protein (CRABP) in the early mouse embryo. Development. 1990; 110(2):343-52. DOI: 10.1242/dev.110.2.343. View

Jahn O, Hesse D, Reinelt M, Kratzin H . Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry. Anal Bioanal Chem. 2006; 386(1):92-103. DOI: 10.1007/s00216-006-0592-1. View

Lopez-Toledano M, Shelanski M . Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci. 2004; 24(23):5439-44. PMC: 6729298. DOI: 10.1523/JNEUROSCI.0974-04.2004. View

Tuschl T . Functional genomics: RNA sets the standard. Nature. 2003; 421(6920):220-1. DOI: 10.1038/421220a. View

Steinacker P, Schwarz P, Reim K, Brechlin P, Jahn O, Kratzin H . Unchanged survival rates of 14-3-3gamma knockout mice after inoculation with pathological prion protein. Mol Cell Biol. 2005; 25(4):1339-46. PMC: 547999. DOI: 10.1128/MCB.25.4.1339-1346.2005. View

10.

Won J, Nam E, Yoo S, Kwon H, Um S, Han H . The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma. Metabolism. 2004; 53(8):1007-12. DOI: 10.1016/j.metabol.2003.12.015. View

11.

Shah J, Cleveland D . Slow axonal transport: fast motors in the slow lane. Curr Opin Cell Biol. 2002; 14(1):58-62. DOI: 10.1016/s0955-0674(01)00294-0. View

12.

Perez-Olle R, Jones S, Liem R . Phenotypic analysis of neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture models. Hum Mol Genet. 2004; 13(19):2207-20. DOI: 10.1093/hmg/ddh236. View

13.

Tuschl T, Zamore P, Lehmann R, Bartel D, Sharp P . Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 2000; 13(24):3191-7. PMC: 317199. DOI: 10.1101/gad.13.24.3191. View

14.

Dencker L, Gustafson A, Annerwall E, Busch C, Eriksson U . Retinoid-binding proteins in craniofacial development. J Craniofac Genet Dev Biol. 1991; 11(4):303-14. View

15.

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

16.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

17.

Scott W, Hauser E, Schmechel D, Welsh-Bohmer K, Small G, Roses A . Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am J Hum Genet. 2003; 73(5):1041-51. PMC: 1180484. DOI: 10.1086/379083. View

18.

Martinez T, Pascual A . Identification of genes differentially expressed in SH-SY5Y neuroblastoma cells exposed to the prion peptide 106-126. Eur J Neurosci. 2007; 26(1):51-9. DOI: 10.1111/j.1460-9568.2007.05646.x. View

19.

Jin K, Peel A, Mao X, Xie L, Cottrell B, Henshall D . Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A. 2003; 101(1):343-7. PMC: 314187. DOI: 10.1073/pnas.2634794100. View

20.

Bertram L, Tanzi R . Of replications and refutations: the status of Alzheimer's disease genetic research. Curr Neurol Neurosci Rep. 2002; 1(5):442-50. DOI: 10.1007/s11910-001-0104-9. View